Skip to main content
Q

Qingdao Vland Biotech Inc. — Investor Relations & Filings

Ticker · 603739 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 986 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603739

About Qingdao Vland Biotech Inc.

Qingdao Vland Biotech Inc. specializes in the research, development, and production of enzymes, probiotics, and animal health solutions. The company provides biological products for diverse applications, including animal nutrition, food processing, textiles, household care, and environmental protection. Its enzyme portfolio encompasses phytases, carbohydrases, and proteases designed to improve feed efficiency and industrial productivity. In the probiotics sector, the firm develops microbial strains for human health and livestock management. Additionally, the company offers veterinary vaccines and pharmaceutical products. By leveraging advanced biotechnology, the organization focuses on delivering sustainable alternatives to traditional chemical processes, aiming to enhance resource efficiency and reduce environmental impact across global supply chains.

Recent filings

Filing Released Lang Actions
青岛蔚蓝生物股份有限公司2025年年度股东会会议材料
Regulatory Filings
2026-05-07 Chinese
中泰证券股份有限公司关于青岛蔚蓝生物股份有限公司2025年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 1% confidence The document is a detailed “核查意见” (review opinion) issued by the sponsor (中泰证券) on the deposit and use of proceeds raised by the company during the 2025 fiscal year. It is not an annual report or earnings release, nor a simple announcement; rather it is a standalone audit‐style compliance report on the use of fundraising proceeds under listing rules. This fits the definition of an Audit Report / Information (Code: AR).
2026-04-24 Chinese
青岛蔚蓝生物股份有限公司2025年度利润分配方案的公告
Notice of Dividend Amount Classification · 1% confidence The document is a corporate announcement detailing the 2025 profit distribution plan, specifying the per-share cash dividend ratio, total dividend amount, conditions for adjustment, and next steps for shareholder approval. It is not the full annual report or an interim report, but rather an announcement of dividend distribution details. This matches the definition for Notice of Dividend Amount (DIV).
2026-04-24 Chinese
青岛蔚蓝生物股份有限公司2026年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 1% confidence The document is an announcement by the board of Qingdao Weilan Bio Co., Ltd. detailing its 2026 “quality improvement, efficiency enhancement, and shareholder return” action plan. It is not a formal Annual Report or Interim Report (no full financial statements), nor a dividend notice (dividend details are secondary to the plan), nor an earnings release, proxy statement, or other defined filing type. It mainly outlines a strategic action plan and governance measures in response to regulatory guidance, fitting a miscellaneous regulatory compliance announcement. Therefore, the most appropriate category is a Regulatory Filing (RNS).
2026-04-24 Chinese
青岛蔚蓝生物股份有限公司2025年度内部控制审计报告
Audit Report / Information Classification · 1% confidence The document is a standalone internal control audit report (“内部控制审计报告”) issued by Grant Thornton under Chinese CPA practice standards, containing audit scope, responsibilities, opinions on internal control effectiveness, and detailed evaluation criteria. It is an audit report, not an announcement or summary. Therefore, it falls squarely under the Audit Report / Information category.
2026-04-24 Chinese
青岛蔚蓝生物股份有限公司关于使用闲置自有资金进行现金管理的公告
Regulatory Filings Classification · 1% confidence The document is an announcement by Qingdao Blue Bio’s board concerning the use of up to RMB 400 million of idle funds to purchase high‐safety, high‐liquidity financial products. It is not a financial report (e.g., Annual/Interim Report or Earnings Release), nor a notice of dividend, equity change, M&A, board change, or proxy solicitation. It does not fit Capital/Financing Update (no new capital raised) or Interest Rate Notice (no rate change). It is a standalone regulatory announcement required by the exchange, so it falls into the fallback category "Regulatory Filings (RNS)".
2026-04-24 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.